These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 24040506)

  • 1. Next-generation therapeutic solutions for age-related macular degeneration.
    Cunnusamy K; Ufret-Vincenty R; Wang S
    Pharm Pat Anal; 2012 May; 1(2):193-206. PubMed ID: 24040506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-VEGF agents for age-related macular degeneration.
    Ozkiris A
    Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
    Lu X; Sun X
    Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of drug options in age-related macular degeneration therapy and potential new agents.
    Yeoh J; Sims J; Guymer RH
    Expert Opin Pharmacother; 2006 Dec; 7(17):2355-68. PubMed ID: 17109611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
    Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
    Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neovascular age-related macular degeneration: potential therapies.
    Chappelow AV; Kaiser PK
    Drugs; 2008; 68(8):1029-36. PubMed ID: 18484796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].
    Meyer CH; Helb HM; Eter N
    Ophthalmologe; 2008 Feb; 105(2):125-38, 140-2. PubMed ID: 18256841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.
    Yang S; Zhao J; Sun X
    Drug Des Devel Ther; 2016; 10():1857-67. PubMed ID: 27330279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising new treatments for neovascular age-related macular degeneration.
    Michels S; Schmidt-Erfurth U; Rosenfeld PJ
    Expert Opin Investig Drugs; 2006 Jul; 15(7):779-93. PubMed ID: 16787141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-VEGF therapy resistance in neovascular age-related macular degeneration].
    Budzinskaya MV; Plyukhova AA; Sorokin PA
    Vestn Oftalmol; 2017; 133(4):103-108. PubMed ID: 28980574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment modalities for age related macular degeneration.
    Das RA; Romano A; Chiosi F; Menzione M; Rinaldi M
    Curr Drug Targets; 2011 Feb; 12(2):182-9. PubMed ID: 20887244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Developments in the Treatment of Wet Age-related Macular Degeneration.
    Papadopoulos Z
    Curr Med Sci; 2020 Oct; 40(5):851-857. PubMed ID: 32980899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of vascular endothelial growth factor inhibition in age-related macular degeneration.
    Mousa SA; Mousa SS
    BioDrugs; 2010 Jun; 24(3):183-94. PubMed ID: 20210371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is there a drug therapy for age-related macular degeneration?--current status and new therapeutic approaches].
    Augustin AJ; Offermann I
    Klin Monbl Augenheilkd; 2008 Jun; 225(6):555-63. PubMed ID: 18516776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current therapeutic approaches in neovascular age-related macular degeneration.
    Nguyen DH; Luo J; Zhang K; Zhang M
    Discov Med; 2013 Jun; 15(85):343-8. PubMed ID: 23819948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors.
    Mehta H; Tufail A; Daien V; Lee AY; Nguyen V; Ozturk M; Barthelmes D; Gillies MC
    Prog Retin Eye Res; 2018 Jul; 65():127-146. PubMed ID: 29305324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
    Feng L; Hu JH; Chen J; Xie X
    J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
    Nguyen TT; Guymer R
    Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration].
    Dyakov IN; Zyryanov SK
    Vestn Oftalmol; 2017; 133(2):125-129. PubMed ID: 28524152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.